Geoffrey Michael Glass is Director at AVADEL PHARMACEUTICALS PLC (AVDL). They have made 7 open-market trades across 1 company since 2019, most recently 2026-02-12.
CIK 0001517718
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $1.0M since 2019, never a sale. Across 7 scored buys the stock is up 40.8% at ninety days, and 41.3 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| AVDL | 22,000 | $476K |
Shares reported on the most recent Form 4, priced at the 2025-07-31 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 14% | 43% | 57% |
| Avg Move | -4.8% | +1.8% | +40.8% |
| Alpha | -1.6% | +4.7% | +41.3% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AVDL | BUY | 2024-12-10 | 2024-12-10 | $9.84 | $399K | -4.6% | -26.9% | -29.6% |
| AVDL | BUY | 2023-08-10 | 2023-08-11 | $13.40 | $188K | -4.5% | -11.4% | -23.7% |
| AVDL | BUY | 2022-06-01 | 2022-06-02 | $2.14 | $96K | -15.4% | +38.5% | +155.4% |
| AVDL | BUY | 2022-05-31 | 2022-06-03 | $2.14 | $96K | -4.5% | +48.8% | +174.4% |
| AVDL | BUY | 2020-08-28 | 2020-09-01 | $6.78 | $33K | -22.3% | -27.4% | +2.0% |
| AVDL | BUY | 2020-08-12 | 2020-08-14 | $7.73 | $100K | -2.6% | -32.2% | -28.7% |
| AVDL | BUY | 2019-11-15 | 2019-11-19 | $4.99 | $100K | +20.2% | +23.1% | +36.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.